PERMAX Side Effects

5956892-8 | Acanthoma, Atrioventricular Block Complete, Bronchitis, Cardiac Failure Congestive, Carotid Bruit, Cervical Cyst, Chronic Fatigue Syndrome, Conjunctival Haemorrhage, Coronary Artery Disease
on Jul 02, 2008 Female patient from UNITED STATES , 40 years of age, was diagnosed with restless legs syndrome, depression (What is depression?) and was treated with Permax (View Usage). Patient experienced the following unwanted or unexpected effects: acanthoma, atrioventricular block complete, bronchitis (What is bronchitis?), cardiac failure congestive, carotid bruit, cervical cyst, chronic fatigue syndrome (What is chronic fatigue syndrome?), conjunctival haemorrhage, coronary artery disease (What is coronary artery disease?). Permax dosage: 0.075 Mg, Daily (1/d). During the same period patient was treated with PROZAC (1 D/f) (View Prozac Review and Prozac Label ), MIRAPEX (View Mirapex Review and Mirapex Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), XANAX (View Xanax Review and Xanax Label ), NARBALEK (CALCIUM PANTOTHENATE, FERROUS FUMARATE, MAGNESIUM ASPARTATE, (View Narbalek (calcium Pantothenate, Ferrous Fumarate, Magnesium Aspartate, Review and Narbalek (calcium Pantothenate, Ferrous Fumarate, Magnesium Aspartate, Label ), ULTRAM (View Ultram Review and Ultram Label ), CLARITIN D (View Claritin-d Review and Claritin-d Label ), FIORICET (View Fioricet Review and Fioricet Label ). Patient was hospitalized.

5873095-6 | Back Pain, Posture Abnormal
Patient was taking Permax (View Usage). Patient had the following side effects: back pain (What is back pain?), posture abnormal on Aug 26, 2008 from JAPAN Additional patient health information: Male patient , 60 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: 100 Ug; Qd; Po. During the same period patient was treated with L DOPA (View L-dopa Review and L-dopa Label ), L DIHYDROXYPHENYLSERINE (View L-dihydroxyphenylserine Review and L-dihydroxyphenylserine Label ).

5859176-1 | Back Pain, Posture Abnormal
Adverse event was reported on Aug 12, 2008 by a Male patient taking Permax (View Usage) (Dosage: 100 Ug Qd Po) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: JAPAN , 65 years of age, After Permax was administered, patient had the following side effects: back pain (What is back pain?), posture abnormal. During the same period patient was treated with L DOPA (View L-dopa Review and L-dopa Label ), L DIHYDROXYPHENYLSERINE (View L-dihydroxyphenylserine Review and L-dihydroxyphenylserine Label ).

5858370-3 | Atrial Fibrillation, Cardiomegaly, Chest X-ray Abnormal, Hepatic Congestion, Mitral Valve Incompetence, Oedema Genital, Oedema Peripheral, Right Ventricular Failure
on Aug 07, 2008 Male patient from JAPAN , 74 years of age, weighting 149.9 lb, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?), cardiomegaly, chest x-ray abnormal, hepatic congestion, mitral valve incompetence, oedema genital, oedema peripheral, right ventricular failure. Permax dosage: 750 Ug; Po, 1500 Ug; Po. During the same period patient was treated with CARBIDOPA + LEVODOPA (View Carbidopa + Levodopa Review and Carbidopa + Levodopa Label ), ARTANE (View Artane Review and Artane Label ), DOMIN (View Domin Review and Domin Label ), PRAMIPEXOLE DIHYDROCHLORIDE (View Pramipexole Dihydrochloride Review and Pramipexole Dihydrochloride Label ), DONEPEZIL HCL (View Donepezil Hcl Review and Donepezil Hcl Label ). Patient was hospitalized.


5844706-6 | Akinesia, Cardiac Aneurysm, Cardiac Valve Disease
on Jul 29, 2008 Female patient from JAPAN , 74 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient had the following side effects: akinesia, cardiac aneurysm, cardiac valve disease. Permax dosage: ; Po, 1500 Ug; Qd; Po, 1250 Ug; Qd; Po, 1000 Ug; Qd; Po. During the same period patient was treated with LEVODOPA BENSERAZIDE HYDROCHLO (View Levodopa Benserazide Hydrochlo Review and Levodopa Benserazide Hydrochlo Label ), SIFROL (View Sifrol Review and Sifrol Label ), SYMMETREL (View Symmetrel Review and Symmetrel Label ). Patient was hospitalized.

5826987-8 | Cardiac Aneurysm, Cardiac Failure Congestive, Cardiac Valve Disease, Dyspnoea, Hydrothorax, Mitral Valve Disease, Mitral Valve Incompetence
Patient was taking Permax (View Usage). After Permax was administered, patient had the following side effects: cardiac aneurysm, cardiac failure congestive, cardiac valve disease, dyspnoea, hydrothorax, mitral valve disease, mitral valve incompetence on Jul 14, 2008 from JAPAN Additional patient health information: Female patient , 74 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: See Image. During the same period patient was treated with LEVODOPA BENSERAZIDE (View Levodopa Benserazide Review and Levodopa Benserazide Label ), HYDROCHLO (View Hydrochlo Review and Hydrochlo Label ), SIFROL (View Sifrol Review and Sifrol Label ), SYMMETREL (View Symmetrel Review and Symmetrel Label ). Patient was hospitalized.

5794930-6 | Dyskinesia, Hypoaesthesia, Limb Discomfort, On And Off Phenomenon, Pruritus, Restless Legs Syndrome, Sensory Disturbance
Adverse event was reported on Jun 19, 2008 by a Female patient taking Permax (View Usage) (Dosage: ) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: JAPAN , 59 years of age, Patient experienced the following unwanted or unexpected effects: dyskinesia, hypoaesthesia, limb discomfort, on and off phenomenon, pruritus, restless legs syndrome, sensory disturbance. During the same period patient was treated with LEVODOPA (View Levodopa Review and Levodopa Label ), AMANTADINE HCL (View Amantadine Hcl Review and Amantadine Hcl Label ). Patient was hospitalized and became disabled.

5793834-2 | Gastric Ulcer Haemorrhage, Tachycardia
on Jun 17, 2008 Male patient from JAPAN , 57 years of age, weighting 163.1 lb, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient had the following side effects: gastric ulcer haemorrhage, tachycardia. Permax dosage: . During the same period patient was treated with DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), ENTACAPONE (View Entacapone Review and Entacapone Label ), CARBIDOPA (View Carbidopa Review and Carbidopa Label ), LEVODOPA (View Levodopa Review and Levodopa Label ), DOMPERIDONE (View Domperidone Review and Domperidone Label ). Patient was hospitalized.

5779198-9 | Left Ventricular Hypertrophy, Mitral Valve Incompetence, Tricuspid Valve Incompetence
on Jun 10, 2008 Female patient from UNITED STATES , 42 years of age, weighting 302.0 lb, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). After Permax was administered, patient had the following side effects: left ventricular hypertrophy, mitral valve incompetence, tricuspid valve incompetence. Permax dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), TYLENOL (CAPLET) (View Tylenol (caplet) Review and Tylenol (caplet) Label ), METFORMIN (View Metformin Review and Metformin Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), IBUROFEN (View Iburofen Review and Iburofen Label ), HYDROCODONE BITARTRATE (View Hydrocodone Bitartrate Review and Hydrocodone Bitartrate Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ).

5776050-X | Bone Fissure, Sleep Attacks, Somnambulism
Patient was taking Permax (View Usage). Patient experienced the following unwanted or unexpected effects: bone fissure, sleep attacks, somnambulism on Jun 09, 2008 from JAPAN Additional patient health information: Male patient , 57 years of age, . Permax dosage: . During the same period patient was treated with MENESIT (View Menesit Review and Menesit Label ).

5775907-3 | Anxiety, Confusional State, Hallucination
Adverse event was reported on Jun 10, 2008 by a Female patient taking Permax (View Usage) (Dosage: ) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: FRANCE , 83 years of age, Patient had the following side effects: anxiety (What is anxiety?), confusional state, hallucination. During the same period patient was treated with MODOPAR (View Modopar Review and Modopar Label ), PAROXETINE HCL (View Paroxetine Hcl Review and Paroxetine Hcl Label ), MOPRAL (View Mopral Review and Mopral Label ).

5773820-9 | Gastrointestinal Haemorrhage
on Jun 03, 2008 Male patient from JAPAN , 65 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). After Permax was administered, patient had the following side effects: gastrointestinal haemorrhage. Permax dosage: . Patient was hospitalized.

5739655-8 | Abasia, Erythromelalgia
on May 02, 2008 Female patient from JAPAN , 66 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient experienced the following unwanted or unexpected effects: abasia, erythromelalgia. Permax dosage: 750 Ug; Qd; Po, 1250 Ug; Qd; Po. During the same period patient was treated with SINEMET (View Sinemet Review and Sinemet Label ), DOPS (DROXIDOPA) (View Dops (droxidopa) Review and Dops (droxidopa) Label ), PRAVASTATIN (View Pravastatin Review and Pravastatin Label ), FLAVOXATE HYDROCHLORIDE (FLAVOXATE HYDROCHLORIDE) (View Flavoxate Hydrochloride (flavoxate Hydrochloride) Review and Flavoxate Hydrochloride (flavoxate Hydrochloride) Label ), PRAMIPEXOLE DIHYDROCHLORIDE (View Pramipexole Dihydrochloride Review and Pramipexole Dihydrochloride Label ), SYMMETREL (View Symmetrel Review and Symmetrel Label ), PURSENNID (SENNA LEAF) (View Pursennid (senna Leaf) Review and Pursennid (senna Leaf) Label ), ZONISAMIDE (View Zonisamide Review and Zonisamide Label ). Patient was hospitalized.

5727294-4 | Aortic Valve Incompetence, Cardiac Valve Disease, Cardiac Valve Sclerosis, Mitral Valve Incompetence, Oedema Peripheral, Overdose, Pulmonary Oedema, Tricuspid Valve Incompetence
Patient was taking Permax (View Usage). Patient had the following side effects: aortic valve incompetence, cardiac valve disease, cardiac valve sclerosis, mitral valve incompetence, oedema peripheral, overdose, pulmonary oedema, tricuspid valve incompetence on Apr 15, 2008 from BELGIUM Additional patient health information: Male patient , 59 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: 0.5 Mg; Tid; Po, 2 Mg; Tid; Po, 2 Mg; Qid; Po, 1 Mg; Qid; Po, 2 Mg; Qid; Po. During the same period patient was treated with LEVODOPA (View Levodopa Review and Levodopa Label ). Patient was hospitalized.

5725879-2 | Abdominal Distension, Confusional State, Dyspnoea, Mitral Valve Incompetence, Myocardial Fibrosis, Oedema Peripheral, Pulmonary Valve Incompetence, Restlessness, Restrictive Cardiomyopathy
Adverse event was reported on Apr 11, 2008 by a Male patient taking Permax (View Usage) (Dosage: ) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: UNITED STATES , 69 years of age, After Permax was administered, patient had the following side effects: abdominal distension, confusional state, dyspnoea, mitral valve incompetence, myocardial fibrosis, oedema peripheral, pulmonary valve incompetence, restlessness, restrictive cardiomyopathy. During the same period patient was treated with ROPINIROLE HCL (View Ropinirole Hcl Review and Ropinirole Hcl Label ), LEVODOPA (View Levodopa Review and Levodopa Label ).

5725711-7 | Cardiac Valve Disease, Heart Valve Incompetence, Hypertension, Inflammation, Localised Oedema, Mitral Valve Incompetence, Oedema Peripheral, Pericardial Fibrosis, Pericarditis
on Apr 11, 2008 Male patient from SPAIN , 78 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac valve disease, heart valve incompetence, hypertension, inflammation, localised oedema, mitral valve incompetence, oedema peripheral, pericardial fibrosis, pericarditis. Permax dosage: . Patient was hospitalized.

5725030-9 | Acute Respiratory Distress Syndrome, Aortic Valve Incompetence, Cardiac Failure Congestive, Delirium, Device Leakage, Mitral Valve Incompetence, Overdose, Peritoneal Effusion, Pleural Effusion
on Apr 11, 2008 Female patient from CANADA , 61 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient had the following side effects: acute respiratory distress syndrome, aortic valve incompetence, cardiac failure congestive, delirium, device leakage, mitral valve incompetence, overdose, peritoneal effusion, pleural effusion. Permax dosage: 1.75 Mg; Qid; Po. During the same period patient was treated with LEVODOPA (View Levodopa Review and Levodopa Label ), CARBIDOPA (View Carbidopa Review and Carbidopa Label ). Patient was hospitalized.

5724980-7 | Acute Pulmonary Oedema, Aortic Valve Incompetence, Condition Aggravated, Dyskinesia, Left Atrial Dilatation, Mitral Valve Incompetence, Overdose, Parkinson's Disease, Pulmonary Hypertension
Patient was taking Permax (View Usage). After Permax was administered, patient had the following side effects: acute pulmonary oedema, aortic valve incompetence, condition aggravated, dyskinesia, left atrial dilatation, mitral valve incompetence, overdose, parkinson's disease (What is parkinson's disease?), pulmonary hypertension (What is pulmonary hypertension?) on Apr 14, 2008 from BELGIUM Additional patient health information: Female patient , 68 years of age, weighting 103.6 lb, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: 2 Mg;tid;po. During the same period patient was treated with PROLOPA (View Prolopa Review and Prolopa Label ), PARLODEL (View Parlodel Review and Parlodel Label ), ELDEPRYL (View Eldepryl Review and Eldepryl Label ), EMCONCOR (View Emconcor Review and Emconcor Label ), NAPROSYN (View Naprosyn Review and Naprosyn Label ), ESTROGEL (View Estrogel Review and Estrogel Label ), DIOVANE (View Diovane Review and Diovane Label ), AMLODPINE (View Amlodpine Review and Amlodpine Label ).

5718728-X | Aortic Valve Disease, Inflammation, Liver Disorder, Osteonecrosis, Pericardial Effusion, Tricuspid Valve Incompetence
Adverse event was reported on Apr 10, 2008 by a Female patient taking Permax (View Usage) (Dosage: 1500 Ug; Qd; Po) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: JAPAN , 77 years of age, Patient experienced the following unwanted or unexpected effects: aortic valve disease, inflammation, liver disorder, osteonecrosis (What is osteonecrosis?), pericardial effusion, tricuspid valve incompetence. During the same period patient was treated with SELEGILINE HCL (View Selegiline Hcl Review and Selegiline Hcl Label ), CERCINE (View Cercine Review and Cercine Label ), THYRADIN S (View Thyradin S Review and Thyradin S Label ), PRAMIPEXOLE DIHYDROCHLORIDE (View Pramipexole Dihydrochloride Review and Pramipexole Dihydrochloride Label ). Patient was hospitalized and became disabled.

5716366-6 | Erythromelalgia
on Apr 10, 2008 Female patient from JAPAN , 66 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient had the following side effects: erythromelalgia. Permax dosage: 750 Ug Qd Po; 1250 Ug Qd Po. During the same period patient was treated with MENESIT (View Menesit Review and Menesit Label ), DOPS (View Dops Review and Dops Label ), PRAVASTATIN SODIUM (View Pravastatin Sodium Review and Pravastatin Sodium Label ), BLADDERON (View Bladderon Review and Bladderon Label ), PRAMIPEXOLE DIHYDROCHLORIDE (View Pramipexole Dihydrochloride Review and Pramipexole Dihydrochloride Label ), SYMMETREL (View Symmetrel Review and Symmetrel Label ), GLYSENNID (View Glysennid Review and Glysennid Label ), EXCEGRAN (View Excegran Review and Excegran Label ). Patient was hospitalized.

5671659-6 | Basophil Percentage Decreased, Eosinophilic Pneumonia Acute, Interstitial Lung Disease, Lymphocyte Percentage Decreased, Lymphocyte Stimulation Test Positive, Monocyte Percentage Decreased, Neutrophil Percentage Decreased, Pleural Calcification, Pleural Effusion
on Mar 05, 2008 Female patient from JAPAN , 81 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). After Permax was administered, patient had the following side effects: basophil percentage decreased, eosinophilic pneumonia acute, interstitial lung disease, lymphocyte percentage decreased, lymphocyte stimulation test positive, monocyte percentage decreased, neutrophil percentage decreased, pleural calcification, pleural effusion. Permax dosage: 100 Ug; Qd; Po, 250 Ug; Qd; Po, 600 Ug;qd; Po, 750 Ug; Qd; Po. During the same period patient was treated with SELEGILINE HYDROCHLORIDE (2.5 Mg; Bid; Po) (View Selegiline Hydrochloride Review and Selegiline Hydrochloride Label ), AMANTADINE HCL (50 Mg; Tid; Po) (View Amantadine Hcl Review and Amantadine Hcl Label ), CLONAZEPAM (0.5 Mg; Tid; Po) (View Clonazepam Review and Clonazepam Label ), LEVODOPA BENSERAZIDE HYDROCHLO (MADOPAR) (View Levodopa Benserazide Hydrochlo (madopar) Review and Levodopa Benserazide Hydrochlo (madopar) Label ). Patient was hospitalized.

5636815-1 | Aortic Valve Disease, Hepatic Function Abnormal, Inflammation, Osteonecrosis, Pericardial Effusion
Patient was taking Permax (View Usage). Patient experienced the following unwanted or unexpected effects: aortic valve disease, hepatic function abnormal, inflammation, osteonecrosis (What is osteonecrosis?), pericardial effusion on Jan 24, 2008 from JAPAN Additional patient health information: Female patient , 77 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: 1500 Ug; Qd; Po. Patient was hospitalized and became disabled.

5636054-4 | Eosinophilic Pneumonia Acute, Interstitial Lung Disease, Lymphocyte Stimulation Test Positive, Pleural Calcification, Pleural Effusion, Pneumocystis Jiroveci Pneumonia, Pneumonia Cytomegaloviral, Pneumonia Primary Atypical, Pneumonitis
Adverse event was reported on Feb 04, 2008 by a Female patient taking Permax (View Usage) (Dosage: 100 Ug;ad;po; 250 Ug;qd;po; 600 Ug;qd;po; 750 Ug;qd;po) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: JAPAN , 81 years of age, Patient had the following side effects: eosinophilic pneumonia acute, interstitial lung disease, lymphocyte stimulation test positive, pleural calcification, pleural effusion, pneumocystis jiroveci pneumonia, pneumonia cytomegaloviral, pneumonia primary atypical, pneumonitis. During the same period patient was treated with SELEGILINE HYDROCHLORIDE (2.5 Mg;bid;po) (View Selegiline Hydrochloride Review and Selegiline Hydrochloride Label ), AMANTADINE HCL (50 Mg;tid;po) (View Amantadine Hcl Review and Amantadine Hcl Label ), CLONAZEPAM (0.5 Mg;tid;po) (View Clonazepam Review and Clonazepam Label ), LEVODOPA BENSERAZIDE HYDROCHLO (MADOPAR) (View Levodopa Benserazide Hydrochlo (madopar) Review and Levodopa Benserazide Hydrochlo (madopar) Label ). Patient was hospitalized.

5632030-6 | Atrial Fibrillation, Cardiac Murmur, Cardiomegaly, Hepatic Congestion, Hip Swelling, Mitral Valve Incompetence, Oedema Genital, Oedema Peripheral
on Feb 04, 2008 Male patient from JAPAN , 74 years of age, weighting 149.9 lb, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). After Permax was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), cardiac murmur, cardiomegaly, hepatic congestion, hip swelling, mitral valve incompetence, oedema genital, oedema peripheral. Permax dosage: 750 Ug; Po, 1500 Ug; Po, 1500 Ug; Po. During the same period patient was treated with CARBIDOPA AND LEVODOPA (View Carbidopa And Levodopa Review and Carbidopa And Levodopa Label ), ARTANE (View Artane Review and Artane Label ), DOMIN (View Domin Review and Domin Label ), PRAMIPEXOLE DIHYDROCHLORIDE (View Pramipexole Dihydrochloride Review and Pramipexole Dihydrochloride Label ), DONEPEZIL HCL (View Donepezil Hcl Review and Donepezil Hcl Label ). Patient was hospitalized.

5614885-4 | Vomiting
on Jan 17, 2008 Female patient from JAPAN , child 1 years of age, weighting 22.05 lb, was treated with Permax (View Usage). Patient experienced the following unwanted or unexpected effects: vomiting. Permax dosage: . Patient was hospitalized.

5614884-2 | Aortic Valve Incompetence, Cardiac Murmur, Left Ventricular Hypertrophy, Mitral Valve Incompetence, Pulmonary Valve Incompetence, Tricuspid Valve Incompetence
Patient was taking Permax (View Usage). Patient had the following side effects: aortic valve incompetence, cardiac murmur, left ventricular hypertrophy, mitral valve incompetence, pulmonary valve incompetence, tricuspid valve incompetence on Nov 02, 2007 from FRANCE Additional patient health information: Male patient , 64 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: 1.5 Mg;tid;po. During the same period patient was treated with DIFRAREL (View Difrarel Review and Difrarel Label ), MODOPAR (View Modopar Review and Modopar Label ), COMTAN (View Comtan Review and Comtan Label ), B12 ^RECIP^ (View B12 ^recip^ Review and B12 ^recip^ Label ). Patient was hospitalized.

5614883-0 | Interstitial Lung Disease
Adverse event was reported on Jan 18, 2008 by a Female patient taking Permax (View Usage) (Dosage: 750 Ug;qd;po) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: JAPAN , 81 years of age, After Permax was administered, patient had the following side effects: interstitial lung disease. During the same period patient was treated with SELEGILINE HYDROCHLORIDE (View Selegiline Hydrochloride Review and Selegiline Hydrochloride Label ), AMANTADINE HCL (View Amantadine Hcl Review and Amantadine Hcl Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), LEVODOPA BENSERAZIDE HYDROCHLO (MADOPAR) (View Levodopa Benserazide Hydrochlo (madopar) Review and Levodopa Benserazide Hydrochlo (madopar) Label ). Patient was hospitalized.

5598097-9 | Congestive Cardiomyopathy, Dyspnoea, Ejection Fraction Decreased, Ventricular Extrasystoles
on Jan 02, 2008 Male patient from GERMANY , 67 years of age, weighting 172.0 lb, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient experienced the following unwanted or unexpected effects: congestive cardiomyopathy, dyspnoea, ejection fraction decreased, ventricular extrasystoles. Permax dosage: 3 Mg; Qd; Po. During the same period patient was treated with MADOPAR (View Madopar Review and Madopar Label ), PK LEVO (View Pk-levo Review and Pk-levo Label ), PK MERZ (View Pk-merz Review and Pk-merz Label ), TOREM (View Torem Review and Torem Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), ACERBON ^ICI^ (View Acerbon ^ici^ Review and Acerbon ^ici^ Label ), NOVODIGAL (View Novodigal Review and Novodigal Label ). Patient was hospitalized.

5584500-7 | Vomiting
on Dec 18, 2007 Female patient from JAPAN , child 1 years of age, weighting 22.05 lb, was treated with Permax (View Usage). Patient had the following side effects: vomiting. Permax dosage: . Patient was hospitalized.

5584487-7 | Aphagia, Pericardial Effusion, Pericarditis, Pleural Effusion
Patient was taking Permax (View Usage). After Permax was administered, patient had the following side effects: aphagia, pericardial effusion, pericarditis, pleural effusion on Apr 19, 2007 from JAPAN Additional patient health information: Male patient , 73 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: 250 Ug;tid;po. During the same period patient was treated with MENESIT (View Menesit Review and Menesit Label ), PARMIPEXOLE (View Parmipexole Review and Parmipexole Label ), PROSTAL (View Prostal Review and Prostal Label ), HARNAL (View Harnal Review and Harnal Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ), MUCODYNE (View Mucodyne Review and Mucodyne Label ), MUCOSAL (View Mucosal Review and Mucosal Label ), AMBROXOL HYDROCHLORIDE (View Ambroxol Hydrochloride Review and Ambroxol Hydrochloride Label ). Patient was hospitalized.

5574236-0 | Chest Pain, Left Ventricular Hypertrophy, Mitral Valve Incompetence, Tricuspid Valve Incompetence
Adverse event was reported on Dec 11, 2007 by a Female patient taking Permax (View Usage) (Dosage: 0.05 Mg; Qd;) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: UNITED STATES , 42 years of age, Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), left ventricular hypertrophy, mitral valve incompetence, tricuspid valve incompetence.

5564262-X | Congestive Cardiomyopathy, Dyspnoea, Ejection Fraction Decreased, Ventricular Extrasystoles
on Nov 27, 2007 Male patient from GERMANY , 67 years of age, weighting 172.0 lb, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient had the following side effects: congestive cardiomyopathy, dyspnoea, ejection fraction decreased, ventricular extrasystoles. Permax dosage: 3 Mg;qd;po. During the same period patient was treated with MADOPAR (View Madopar Review and Madopar Label ), PK LEVO (View Pk-levo Review and Pk-levo Label ), PK MERZ (View Pk-merz Review and Pk-merz Label ), TOREM (View Torem Review and Torem Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), ACETYLSALICYLIC ACID SRT (View Acetylsalicylic Acid Srt Review and Acetylsalicylic Acid Srt Label ), ACERBON ^ICI^ (View Acerbon ^ici^ Review and Acerbon ^ici^ Label ), NOVODIGAL (View Novodigal Review and Novodigal Label ). Patient was hospitalized.

5564261-8 | Aortic Valve Incompetence, Blood Ph Decreased, Blood Pressure Decreased, Cardiac Failure, Haemodialysis, Lymphadenopathy, Mitral Valve Incompetence, Pleural Effusion
on Nov 27, 2007 Female patient from JAPAN , 85 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). After Permax was administered, patient had the following side effects: aortic valve incompetence, blood ph decreased, blood pressure decreased, cardiac failure, haemodialysis, lymphadenopathy, mitral valve incompetence, pleural effusion. Permax dosage: 150 Ug;qd;po;250 Ug;qd;po;250 Ug;bid;po;250 Ug;tid;po. During the same period patient was treated with MADOPAR (View Madopar Review and Madopar Label ), SEDIEL (View Sediel Review and Sediel Label ), LUVOX (View Luvox Review and Luvox Label ), ALOSENN (View Alosenn Review and Alosenn Label ), NAUZELIN (View Nauzelin Review and Nauzelin Label ). Patient was hospitalized.

5532158-5 | Cardiac Aneurysm, Cardiac Disorder, Cardiac Failure Congestive, Cardiac Valve Disease, Hydrothorax, Mitral Valve Incompetence, Mitral Valve Sclerosis, Myocardial Infarction
Patient was taking Permax (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac aneurysm, cardiac disorder, cardiac failure congestive, cardiac valve disease, hydrothorax, mitral valve incompetence, mitral valve sclerosis, myocardial infarction on Nov 16, 2007 from JAPAN Additional patient health information: Female patient , 74 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: Po;1500 Ug;qd;po; 1250 Ug;qd;po; 1000 Ug;qd;p0. During the same period patient was treated with LEVODOPA BENSERAZIDE (View Levodopa Benserazide Review and Levodopa Benserazide Label ), HYDROCHLO (View Hydrochlo Review and Hydrochlo Label ), SIFROL (View Sifrol Review and Sifrol Label ), SYMMETREL (View Symmetrel Review and Symmetrel Label ). Patient was hospitalized.

5519302-0 | Altered State Of Consciousness, Dehydration, Hallucination, Visual, Neuroleptic Malignant Syndrome, Somnolence, White Blood Cell Count Increased
Adverse event was reported on Nov 02, 2007 by a Male patient taking Permax (View Usage) (Dosage: 500 Ug; Qd; Po, 750 Ug; Qd; Po, 250 Ug; Bid; Po, 250 Ug; Tid; Po) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: JAPAN , 79 years of age, weighting 115.1 lb, Patient had the following side effects: altered state of consciousness, dehydration, hallucination, visual, neuroleptic malignant syndrome, somnolence, white blood cell count increased. During the same period patient was treated with NEODOPASOL (View Neodopasol Review and Neodopasol Label ), RISPERIDINE (View Risperidine Review and Risperidine Label ), DOPS (View Dops Review and Dops Label ). Patient was hospitalized.

5519301-9 | Aortic Valve Incompetence, Blood Pressure Decreased, Cardiac Failure, Cardiac Murmur, Haemodialysis, Lymphadenopathy, Mitral Valve Incompetence, Oedema
on Nov 02, 2007 Female patient from JAPAN , 85 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). After Permax was administered, patient had the following side effects: aortic valve incompetence, blood pressure decreased, cardiac failure, cardiac murmur, haemodialysis, lymphadenopathy, mitral valve incompetence, oedema. Permax dosage: 150 Ug; Qd; Po, 250 Ug; Qd; Po, 250 Ug; Bid; Po, 250 Ug; Tid; Po. During the same period patient was treated with MADOPAR (View Madopar Review and Madopar Label ), SEDIEL (View Sediel Review and Sediel Label ), LUVOX (View Luvox Review and Luvox Label ), ALOSENN (View Alosenn Review and Alosenn Label ), NAUZELIN (View Nauzelin Review and Nauzelin Label ). Patient was hospitalized.

5519299-3 | Aortic Valve Incompetence, Blood Pressure Decreased, Cardiac Failure, Disease Recurrence, Fatigue, Haemodialysis, Mitral Valve Incompetence, No Therapeutic Response, Oedema Peripheral
on Nov 02, 2007 Female patient from JAPAN , 85 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient experienced the following unwanted or unexpected effects: aortic valve incompetence, blood pressure decreased, cardiac failure, disease recurrence, fatigue, haemodialysis, mitral valve incompetence, no therapeutic response, oedema peripheral. Permax dosage: 150 Ug; Qd; Po, 250 Ug; Qd; Po, 250 Ug; Bid; Po, 250 Ug; Tid; Po. During the same period patient was treated with MADOPAR (View Madopar Review and Madopar Label ), SEDIEL (View Sediel Review and Sediel Label ), LUVOX (View Luvox Review and Luvox Label ), ALOSENN (View Alosenn Review and Alosenn Label ), NAUZELIN (View Nauzelin Review and Nauzelin Label ). Patient was hospitalized.

5519293-2 | Cardiac Aneurysm, Cardiac Failure Congestive, Cardiac Valve Disease, Mitral Valve Incompetence, Myocardial Infarction
Patient was taking Permax (View Usage). Patient had the following side effects: cardiac aneurysm, cardiac failure congestive, cardiac valve disease, mitral valve incompetence, myocardial infarction on Nov 01, 2007 from JAPAN Additional patient health information: Female patient , 74 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: Po, 1500 Ug; Qd; Po, 1250 Ug;qd; Po, 1000 Ug; Qd; Po. During the same period patient was treated with LEVODOPA BENSERAZIDE (View Levodopa Benserazide Review and Levodopa Benserazide Label ), HYDROCHLO (View Hydrochlo Review and Hydrochlo Label ), SYMMETREL (View Symmetrel Review and Symmetrel Label ), SIFROL (View Sifrol Review and Sifrol Label ). Patient was hospitalized.

5515922-8 | Accidental Exposure, Circulatory Collapse, Hypotension
Adverse event was reported on Oct 29, 2007 by a Male patient taking Permax (View Usage) (Dosage: ) . Location: GERMANY , 54 years of age, After Permax was administered, patient had the following side effects: accidental exposure, circulatory collapse, hypotension. During the same period patient was treated with RAMIPRIL (View Ramipril Review and Ramipril Label ). Patient was hospitalized.

5510128-0 | Cardiac Aneurysm, Cardiac Disorder, Cardiac Failure Congestive, Cardiac Valve Disease, Dyspnoea, Echocardiogram Abnormal, Mitral Valve Prolapse, Mitral Valve Sclerosis
on Oct 22, 2007 Female patient from JAPAN , 74 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac aneurysm, cardiac disorder, cardiac failure congestive, cardiac valve disease, dyspnoea, echocardiogram abnormal, mitral valve prolapse, mitral valve sclerosis. Permax dosage: ; Po, 1500 Ug; Qd; Po, 1250 Ug; Qd; Po, 1000 Ug; Qd; Po. During the same period patient was treated with LEVODOPA BENSERAZIDE HYDROCHLORIDE (View Levodopa Benserazide Hydrochloride Review and Levodopa Benserazide Hydrochloride Label ), SIFROL (View Sifrol Review and Sifrol Label ), SYMMETREL (View Symmetrel Review and Symmetrel Label ). Patient was hospitalized.

5483160-3 | Retroperitoneal Fibrosis
on Oct 03, 2007 Male patient from ITALY , 54 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient had the following side effects: retroperitoneal fibrosis. Permax dosage: 4 Mg;qd;po. During the same period patient was treated with LEVODOPA (View Levodopa Review and Levodopa Label ). Patient was hospitalized.

5477474-0 | Blepharospasm, Condition Aggravated, Parkinson's Disease, Visual Acuity Reduced
Patient was taking Permax (View Usage). After Permax was administered, patient had the following side effects: blepharospasm, condition aggravated, parkinson's disease (What is parkinson's disease?), visual acuity reduced on Sep 13, 2007 from JAPAN Additional patient health information: Male patient , 75 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: 1000 Ug; Qd; Po. During the same period patient was treated with CABERGOLINE (View Cabergoline Review and Cabergoline Label ), SIFROL (View Sifrol Review and Sifrol Label ).

5473234-5 | Retroperitoneal Fibrosis, Urethral Stenosis
Adverse event was reported on Sep 18, 2007 by a Male patient taking Permax (View Usage) (Dosage: 4 Mg; Qd; Po) was diagnosed with parkinson's disease (What is parkinson's disease?) and. Location: ITALY , 54 years of age, Patient experienced the following unwanted or unexpected effects: retroperitoneal fibrosis, urethral stenosis. Patient was hospitalized.

5451968-6 | Blepharospasm, Condition Aggravated, Parkinson's Disease, Visual Acuity Reduced
on Aug 29, 2007 Male patient from JAPAN , 75 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). Patient had the following side effects: blepharospasm, condition aggravated, parkinson's disease (What is parkinson's disease?), visual acuity reduced. Permax dosage: 1000 Ug; Qd; Po. During the same period patient was treated with CABERGOLINE (View Cabergoline Review and Cabergoline Label ), SIFROL (View Sifrol Review and Sifrol Label ).

5416523-2 | Ascites, Colon Operation
on Aug 02, 2007 Male patient from JAPAN , 73 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and was treated with Permax (View Usage). After Permax was administered, patient had the following side effects: ascites, colon operation. Permax dosage: 1000 Ug; ; Po. During the same period patient was treated with BROMOCRIPTINE MESYLATE (View Bromocriptine Mesylate Review and Bromocriptine Mesylate Label ), NEO DOPASTON (View Neo Dopaston Review and Neo Dopaston Label ), SELEGILINE HYDROCHLORIDE (View Selegiline Hydrochloride Review and Selegiline Hydrochloride Label ), DEPAS (View Depas Review and Depas Label ), PURSENNID (View Pursennid Review and Pursennid Label ), LAXOBERON (View Laxoberon Review and Laxoberon Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ). Patient was hospitalized.

5394924-9 | Ascites
Patient was taking Permax (View Usage). Patient experienced the following unwanted or unexpected effects: ascites on Jul 10, 2007 from JAPAN Additional patient health information: Male patient , 73 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: Po. During the same period patient was treated with BROMOCRIPTINE MESYLATE (View Bromocriptine Mesylate Review and Bromocriptine Mesylate Label ).

5387178-0 | Acanthoma, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Atrioventricular Block Complete, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Blood Iron Increased, Carotid Bruit, Cervical Cyst
Adverse event was reported on Jul 02, 2007 by a Female patient taking Permax (View Usage) (Dosage: See Image) was diagnosed with restless legs syndrome and. Location: UNITED STATES , 45 years of age, Patient had the following side effects: acanthoma, alanine aminotransferase increased, aspartate aminotransferase increased, atrioventricular block complete, blood alkaline phosphatase increased, blood bilirubin increased, blood iron increased, carotid bruit, cervical cyst. During the same period patient was treated with NARBALEK (View Narbalek Review and Narbalek Label ), DEPO MEDROL + LIDOCAINE (View Depo-medrol + Lidocaine Review and Depo-medrol + Lidocaine Label ), ULTRAM (View Ultram Review and Ultram Label ), PRAMIPEXOLE DIHYDROCHLORIDE (View Pramipexole Dihydrochloride Review and Pramipexole Dihydrochloride Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

5385246-0 | Acanthoma, Antinuclear Antibody Positive, Arthropathy, Atrioventricular Block Complete, Blood Iron Increased, Bursitis, Cardiac Murmur, Carotid Bruit, Cervical Cyst
on Jun 15, 2007 Female patient from UNITED STATES , 45 years of age, was diagnosed with restless legs syndrome and was treated with Permax (View Usage). After Permax was administered, patient had the following side effects: acanthoma, antinuclear antibody positive, arthropathy, atrioventricular block complete, blood iron increased, bursitis (What is bursitis?), cardiac murmur, carotid bruit, cervical cyst. Permax dosage: See Image. During the same period patient was treated with NARBALEK (View Narbalek Review and Narbalek Label ), DEPO MEDROL + LIDOCAINE (View Depo-medrol + Lidocaine Review and Depo-medrol + Lidocaine Label ), ULTRAM (View Ultram Review and Ultram Label ), PRAMIPEXOLE DIHYDROCHLORIDE (View Pramipexole Dihydrochloride Review and Pramipexole Dihydrochloride Label ). Patient was hospitalized.

5363044-1 | Acanthoma, Alanine Aminotransferase Increased, Antinuclear Antibody Positive, Arthropathy, Aspartate Aminotransferase Increased, Atrioventricular Block Complete, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Bursitis
on May 31, 2007 Female patient from UNITED STATES , 45 years of age, was diagnosed with restless legs syndrome and was treated with Permax (View Usage). Patient experienced the following unwanted or unexpected effects: acanthoma, alanine aminotransferase increased, antinuclear antibody positive, arthropathy, aspartate aminotransferase increased, atrioventricular block complete, blood alkaline phosphatase increased, blood bilirubin increased, bursitis (What is bursitis?). Permax dosage: See Image. During the same period patient was treated with NARBALEK (View Narbalek Review and Narbalek Label ), DEPO MEDROL + LIDOCAINE (View Depo-medrol + Lidocaine Review and Depo-medrol + Lidocaine Label ), ULTRAM (View Ultram Review and Ultram Label ), PRAMIPEXOLE DIHYDROCHLORIDE (View Pramipexole Dihydrochloride Review and Pramipexole Dihydrochloride Label ). Patient was hospitalized.

5337875-8 | Affect Lability, Antisocial Personality Disorder, Bereavement Reaction, Cellulitis Gangrenous, Chest Pain, Depression, Diabetes Mellitus, Dizziness, Dyskinesia
Patient was taking Permax (View Usage). Patient had the following side effects: affect lability, antisocial personality disorder, bereavement reaction, cellulitis gangrenous, chest pain (What is chest pain?), depression (What is depression?), diabetes mellitus, dizziness (What is dizziness?), dyskinesia on Feb 22, 2006 from UNITED STATES Additional patient health information: Male patient , 58 years of age, was diagnosed with parkinson's disease (What is parkinson's disease?) and. Permax dosage: See Image. During the same period patient was treated with SINEMET (View Sinemet Review and Sinemet Label ), PRAMIPEXOLE DIHYDROCHLORIDE (View Pramipexole Dihydrochloride Review and Pramipexole Dihydrochloride Label ), COMTAN (View Comtan Review and Comtan Label ), ROPINIROLE HCL (View Ropinirole Hcl Review and Ropinirole Hcl Label ), VICODIN (View Vicodin Review and Vicodin Label ). Patient was hospitalized.